SLC5A2 and type 2 diabetes mellitus: Empagliflozin (EMPA) is a well-known sodium-glucose cotransporter-2 (SGLT-2) inhibitor currently used orally as a treatment for type 2 diabetes mellitus (T2DM) [20].